Ercan Türkmen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ercan Türkmen has a total of 280 co-authors. Here are the top co-authors by number of shared publications:
- Hayriye Sayarlioglu
Department of Nephrology 19 Mayis University Faculty of Medicine Samsun Turkey
5 shared publications - Nurol Arik
Ondokuz Mayis University
5 shared publications - Melda Dilek
Ondokuz Mayis University, School of Medicine
4 shared publications - Tolga Yildirim
Department of Nephrology, Hacettepe University Hospital, Ankara, Turkey
4 shared publications - Ebru Gök Oğuz
Department of Nephrology, Etlik City Hospital, Ankara, Türkiye
3 shared publications - Ferah Taran
Ondokuz Mayis University
3 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (40) , e50881
The impact of tacrolimus variability on first year renal function in kidney transplant recipients
Tacrolimus is a key immunosuppressant with a narrow therapeutic range in kidney transplantation. Early fluctuations in trough concentrations may influence graft stability, yet the clinical significance of early intrapatient variability remains uncertain. This study aimed to evaluate whether tacrolimus variability during the first posttransplant month is associated with renal function at 12 months. This single-center retrospective cohort study included adult kidney transplant recipients receiving tacrolimus-based immunosuppression between January 2017 and December 2021. Tacrolimus variability was quantified as the absolute difference (Δ, ng/mL) between maximum and minimum trough concentrations during the first 30 days, classified as high (Δ > 8 ng/mL) or low (Δ ≤ 8 ng/mL). Renal function was assessed using eGFR at 1, 3, 6, and 12 months. Statistical analyses applied appropriate parametric and nonparametric tests with a significance level of P < .05. High variability was associated with more frequent subtherapeutic and supratherapeutic trough concentrations and transient reductions in early graft performance. However, 12-month eGFR was not significantly different between variability groups. In multivariable models, recipient age, donor age, and biopsy-proven graft dysfunction were consistently associated with lower eGFR across follow-up. Male donor sex showed a positive association with eGFR only at 6 months, whereas early tacrolimus variability was not independently associated with eGFR at any time point.
- 2 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (40) , e50881
Open AccessThe impact of tacrolimus variability on first year renal function in kidney transplant recipients
Tacrolimus is a key immunosuppressant with a narrow therapeutic range in kidney transplantation. Early fluctuations in trough concentrations may influence graft stability, yet the clinical significance of early intrapatient variability remains uncertain. This study aimed to evaluate whether tacrolimus variability during the first posttransplant month is associated with renal function at 12 months. This single-center retrospective cohort study included adult kidney transplant recipients receiving tacrolimus-based immunosuppression between January 2017 and December 2021. Tacrolimus variability was quantified as the absolute difference (Δ, ng/mL) between maximum and minimum trough concentrations during the first 30 days, classified as high (Δ > 8 ng/mL) or low (Δ ≤ 8 ng/mL). Renal function was assessed using eGFR at 1, 3, 6, and 12 months. Statistical analyses applied appropriate parametric and nonparametric tests with a significance level of P < .05. High variability was associated with more frequent subtherapeutic and supratherapeutic trough concentrations and transient reductions in early graft performance. However, 12-month eGFR was not significantly different between variability groups. In multivariable models, recipient age, donor age, and biopsy-proven graft dysfunction were consistently associated with lower eGFR across follow-up. Male donor sex showed a positive association with eGFR only at 6 months, whereas early tacrolimus variability was not independently associated with eGFR at any time point.
- Open Access
- 1 October 2026
- Published by Elsevier in SSRN Electronic Journal
Death With a Functioning Graft Exceeds Graft Failure After Kidney Transplantation: A Single-Center Competing-Risks Analysis
ObjectivesA kidney graft may be lost through intrinsic graft failure or through death of the recipient with a functioning graft, competing events that may have distinct determinants; we compared them in a single-center cohort.MethodsWe retrospectively analyzed 425 adults transplanted during 2008–2022. Graft failure and death with a functioning graft were analyzed as competing events (Aalen–Johansen cumulative incidence); determinants were assessed by cause-specific Cox models, with Fine–Gray models as sensitivity analyses.ResultsThere were 196 living- and 229 deceased-donor recipients (median follow-up 68 months). Patient survival was 88.5% and 71.7% at 5 and 10 years and was higher for living donors (P = .006). Forty-three recipients experienced graft failure whereas 66 died with a functioning graft; the 10-year cumulative incidence of death with a functioning graft (25.6%) exceeded that of graft failure (16.2%). Infection was the leading cause of death (45.8%), including coronavirus disease 2019 (22.2%). Older age (P < .001) and coronary artery disease (P = .009) predicted death and living donation was protective (P = .019), whereas graft loss was predicted only by biopsy-proven rejection (P < .001); findings were concordant in Fine–Gray models.ConclusionsFunctioning grafts were lost more often through patient death than through graft failure. Death was determined by age, cardiovascular disease, and infection, and graft loss by rejection.
- 1 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDeath With a Functioning Graft Exceeds Graft Failure After Kidney Transplantation: A Single-Center Competing-Risks Analysis
ObjectivesA kidney graft may be lost through intrinsic graft failure or through death of the recipient with a functioning graft, competing events that may have distinct determinants; we compared them in a single-center cohort.MethodsWe retrospectively analyzed 425 adults transplanted during 2008–2022. Graft failure and death with a functioning graft were analyzed as competing events (Aalen–Johansen cumulative incidence); determinants were assessed by cause-specific Cox models, with Fine–Gray models as sensitivity analyses.ResultsThere were 196 living- and 229 deceased-donor recipients (median follow-up 68 months). Patient survival was 88.5% and 71.7% at 5 and 10 years and was higher for living donors (P = .006). Forty-three recipients experienced graft failure whereas 66 died with a functioning graft; the 10-year cumulative incidence of death with a functioning graft (25.6%) exceeded that of graft failure (16.2%). Infection was the leading cause of death (45.8%), including coronavirus disease 2019 (22.2%). Older age (P < .001) and coronary artery disease (P = .009) predicted death and living donation was protective (P = .019), whereas graft loss was predicted only by biopsy-proven rejection (P < .001); findings were concordant in Fine–Gray models.ConclusionsFunctioning grafts were lost more often through patient death than through graft failure. Death was determined by age, cardiovascular disease, and infection, and graft loss by rejection.
- Open Access
- 23 September 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (9) , e70473
Long‐Term Renal Function and Clinical Outcomes of Sacubitril/Valsartan in HFrEF and Stage 3–4 Chronic Kidney Disease: A 24‐Month Single‐Centre Cohort
Background: Stage 3–4 chronic kidney disease (CKD) is common in heart failure with reduced ejection fraction (HFrEF) but remains underrepresented in angiotensin receptor–neprilysin inhibitor (ARNI) trials, fostering reluctance to initiate sacubitril/valsartan (S/V). Hypothesis: We hypothesized that, over 24 months, S/V would be associated with stable renal function and acceptable clinical outcomes; the study was designed to be descriptive rather than comparative. Methods: We retrospectively analyzed 360 adults with HFrEF (LVEF < 40%) and predialysis stage 3–4 CKD who initiated S/V (2017–2023) and were followed for up to 24 months; decedents were analyzed as events, not excluded. The primary renal composite (sustained ≥ 30% eGFR decline, chronic dialysis, or end‐stage kidney disease) was analyzed with competing‐risk methods (Aalen–Johansen and Fine–Gray, with death competing); mortality with Cox regression; longitudinal eGFR with mixed‐effects; and sparse‐event models with Firth penalization. Results: Among survivors, mean eGFR was stable (mixed‐model slope non‐significant), with no creatinine rise; NT‐proBNP and CRP fell (both p < 0.001) and NYHA class improved. The renal composite occurred in 12/360 (3.3%); all‐cause and cardiovascular mortality were 6.1% and 3.9%. Lower baseline eGFR was associated with the renal composite. Analyzes of maintenance dose and concomitant SGLT2‐inhibitor use were confounded by treatment tolerance and calendar era and were hypothesis‐generating only. Conclusions: In this single‐arm cohort of HFrEF with stage 3–4 CKD, S/V was generally well tolerated, with stable renal function and low event rates over 24 months. These descriptive, hypothesis‐generating findings cannot establish comparative benefit and require confirmation in controlled studies.
- 23 September 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (9) , e70473
Open AccessLong‐Term Renal Function and Clinical Outcomes of Sacubitril/Valsartan in HFrEF and Stage 3–4 Chronic Kidney Disease: A 24‐Month Single‐Centre Cohort
Background: Stage 3–4 chronic kidney disease (CKD) is common in heart failure with reduced ejection fraction (HFrEF) but remains underrepresented in angiotensin receptor–neprilysin inhibitor (ARNI) trials, fostering reluctance to initiate sacubitril/valsartan (S/V). Hypothesis: We hypothesized that, over 24 months, S/V would be associated with stable renal function and acceptable clinical outcomes; the study was designed to be descriptive rather than comparative. Methods: We retrospectively analyzed 360 adults with HFrEF (LVEF < 40%) and predialysis stage 3–4 CKD who initiated S/V (2017–2023) and were followed for up to 24 months; decedents were analyzed as events, not excluded. The primary renal composite (sustained ≥ 30% eGFR decline, chronic dialysis, or end‐stage kidney disease) was analyzed with competing‐risk methods (Aalen–Johansen and Fine–Gray, with death competing); mortality with Cox regression; longitudinal eGFR with mixed‐effects; and sparse‐event models with Firth penalization. Results: Among survivors, mean eGFR was stable (mixed‐model slope non‐significant), with no creatinine rise; NT‐proBNP and CRP fell (both p < 0.001) and NYHA class improved. The renal composite occurred in 12/360 (3.3%); all‐cause and cardiovascular mortality were 6.1% and 3.9%. Lower baseline eGFR was associated with the renal composite. Analyzes of maintenance dose and concomitant SGLT2‐inhibitor use were confounded by treatment tolerance and calendar era and were hypothesis‐generating only. Conclusions: In this single‐arm cohort of HFrEF with stage 3–4 CKD, S/V was generally well tolerated, with stable renal function and low event rates over 24 months. These descriptive, hypothesis‐generating findings cannot establish comparative benefit and require confirmation in controlled studies.
- Open Access
- 7 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (2) , 163-170
Current Status of Kidney Replacement Therapy in Türkiye: A Summary of 2024 Turkish Society of Nephrology Registry Repor
Background: The Turkish Society of Nephrology registry annually collects nationwide data on hemodialysis, peritoneal dialysis (PD), and kidney transplantation. Registry findings are published annually; the current report marks the thirty-fifth year of data collection. The registry is in close collaboration with international registries. Methods: This study summarized data from the 2024 registry report and provided yearly trends in the management of end-stage kidney disease. Results: The number of patients receiving kidney replacement therapy continued to rise, reaching 92 461 individuals by the end of 2024. The prevalence and incidence of end-stage kidney disease were 1079.3 and 164 per million population, respec tively. Diabetes mellitus remained the leading cause of end-stage kidney disease. Hemodialysis was the most common type of treatment modality (70.4%), followed by kidney transplantation (25.4%) and PD (4.2%). Conclusion: End-stage kidney disease remains a major and expanding public health challenge in Türkiye. The kidney reg istry of the Turkish Society of Nephrology is one of the leading tools for providing current and sound data on this public health problem. Cite this article as: Seyahi N, Koçyiğit İ, Dinçer MT, et al. Current status of kidney replacement therapy in Türkiye: A summary of 2024 Turkish Society of Nephrology Registry Report. Turk J Nephrol. 2026;35(2):163-170.
- 7 April 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (2) , 163-170
Open AccessCurrent Status of Kidney Replacement Therapy in Türkiye: A Summary of 2024 Turkish Society of Nephrology Registry Repor
Background: The Turkish Society of Nephrology registry annually collects nationwide data on hemodialysis, peritoneal dialysis (PD), and kidney transplantation. Registry findings are published annually; the current report marks the thirty-fifth year of data collection. The registry is in close collaboration with international registries. Methods: This study summarized data from the 2024 registry report and provided yearly trends in the management of end-stage kidney disease. Results: The number of patients receiving kidney replacement therapy continued to rise, reaching 92 461 individuals by the end of 2024. The prevalence and incidence of end-stage kidney disease were 1079.3 and 164 per million population, respec tively. Diabetes mellitus remained the leading cause of end-stage kidney disease. Hemodialysis was the most common type of treatment modality (70.4%), followed by kidney transplantation (25.4%) and PD (4.2%). Conclusion: End-stage kidney disease remains a major and expanding public health challenge in Türkiye. The kidney reg istry of the Turkish Society of Nephrology is one of the leading tools for providing current and sound data on this public health problem. Cite this article as: Seyahi N, Koçyiğit İ, Dinçer MT, et al. Current status of kidney replacement therapy in Türkiye: A summary of 2024 Turkish Society of Nephrology Registry Report. Turk J Nephrol. 2026;35(2):163-170.
- Open Access
- 15 April 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 34 (2) , 141-148
Current Status of Kidney Replacement Therapy in Türkiye: A Summary of 2023 Turkish Society of Nephrology Registry Report
Background: Turkish Society of Nephrology registry collects data on hemodialysis, peritoneal dialysis (PD), and transplan tation annually. Registry reports are printed every year as a booklet, and this is the 34th year of the registry reports. The registry is in close collaboration with international registries. Methods: In this paper, we summarized data from the 2023 registry report and provided yearly trends for managing end stage kidney disease. Results: The number of patients on kidney replacement therapy (KRT) increased; at the end of 2023, 89 527 patients were on KRT. The prevalence and incidence of end-stage kidney disease were 1048.7 and 159.8 per million population, respec tively. Diabetes was the most common cause of end-stage kidney disease. Hemodialysis (70.88%) was the most common type of treatment modality, followed by transplantation (25.01%) and PD (4.11%). Conclusion: End-stage kidney disease is a critical and growing health problem for our country. The kidney registry of the Turkish Society of Nephrology is one of the leading tools for providing current and sound data on this public health problem. Cite this article as: Seyahi N, Koçyi#it ", Eren N, et!al. Current Status of Kidney Replacement Therapy in Türkiye: A Summary of 2023 Turkish Society of Nephrology Registry Report. Turk J Nephrol. 2025;34(2):141-148.
- 15 April 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 34 (2) , 141-148
Open AccessCurrent Status of Kidney Replacement Therapy in Türkiye: A Summary of 2023 Turkish Society of Nephrology Registry Report
Background: Turkish Society of Nephrology registry collects data on hemodialysis, peritoneal dialysis (PD), and transplan tation annually. Registry reports are printed every year as a booklet, and this is the 34th year of the registry reports. The registry is in close collaboration with international registries. Methods: In this paper, we summarized data from the 2023 registry report and provided yearly trends for managing end stage kidney disease. Results: The number of patients on kidney replacement therapy (KRT) increased; at the end of 2023, 89 527 patients were on KRT. The prevalence and incidence of end-stage kidney disease were 1048.7 and 159.8 per million population, respec tively. Diabetes was the most common cause of end-stage kidney disease. Hemodialysis (70.88%) was the most common type of treatment modality, followed by transplantation (25.01%) and PD (4.11%). Conclusion: End-stage kidney disease is a critical and growing health problem for our country. The kidney registry of the Turkish Society of Nephrology is one of the leading tools for providing current and sound data on this public health problem. Cite this article as: Seyahi N, Koçyi#it ", Eren N, et!al. Current Status of Kidney Replacement Therapy in Türkiye: A Summary of 2023 Turkish Society of Nephrology Registry Report. Turk J Nephrol. 2025;34(2):141-148.
- Open Access
- 25 February 2025
- Published by Hitit University in Hitit Medical Journal
- Vol. 7 (1) , 37-44
Ferritin and Cardiac Electrophysiology in End-Stage Renal Disease: Evaluating the Impact of Index of Cardio-Electrophysiological Balance
Objective: Ferritin is a critical protein involved in iron storage and functions as an acute-phase reactant, playing a significant role in chronic inflammation and the pathogenesis of cardiovascular diseases. Elevated ferritin levels in end-stage renal disease patients undergoing hemodialysis may influence cardiac electrophysiological parameters, such as the corrected index of cardio-electrophysiological balance, a marker of proarrhythmic risk. This study aimed to investigate the association between ferritin levels and the corrected index of cardio-electrophysiological balance in patients with end-stage renal disease undergoing hemodialysis. Material and Method: This retrospective cross-sectional study included 438 patients with end-stage renal disease undergoing hemodialysis, categorized into two groups according to their ferritin levels: Group 1 (≥1000 ng/mL, n=254) and Group 2 (≤200 ng/mL, n=184). Demographic, biochemical, and electrocardiographic data, including corrected index of cardio-electrophysiological balance, were analyzed. The correlation between ferritin levels and the corrected index of cardio-electrophysiological balance was assessed. Results: The index of cardio-electrophysiological balance was significantly higher in Group 1 compared to Group 2 (5.1 vs. 4.9, p=0.003). A moderate positive correlation between ferritin levels and the index of cardio-electrophysiological balance was identified (r=0.326, p
- 25 February 2025
- Published by Hitit University in Hitit Medical Journal
- Vol. 7 (1) , 37-44
Open AccessFerritin and Cardiac Electrophysiology in End-Stage Renal Disease: Evaluating the Impact of Index of Cardio-Electrophysiological Balance
Objective: Ferritin is a critical protein involved in iron storage and functions as an acute-phase reactant, playing a significant role in chronic inflammation and the pathogenesis of cardiovascular diseases. Elevated ferritin levels in end-stage renal disease patients undergoing hemodialysis may influence cardiac electrophysiological parameters, such as the corrected index of cardio-electrophysiological balance, a marker of proarrhythmic risk. This study aimed to investigate the association between ferritin levels and the corrected index of cardio-electrophysiological balance in patients with end-stage renal disease undergoing hemodialysis. Material and Method: This retrospective cross-sectional study included 438 patients with end-stage renal disease undergoing hemodialysis, categorized into two groups according to their ferritin levels: Group 1 (≥1000 ng/mL, n=254) and Group 2 (≤200 ng/mL, n=184). Demographic, biochemical, and electrocardiographic data, including corrected index of cardio-electrophysiological balance, were analyzed. The correlation between ferritin levels and the corrected index of cardio-electrophysiological balance was assessed. Results: The index of cardio-electrophysiological balance was significantly higher in Group 1 compared to Group 2 (5.1 vs. 4.9, p=0.003). A moderate positive correlation between ferritin levels and the index of cardio-electrophysiological balance was identified (r=0.326, p
- Open Access
- 28 November 2023
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 33 (1) , 33-39
Clinical Skills Training: Do Medical Students Have Enough Knowledge of Accurate Blood Pressure Measurement When They Graduate?
Objective: Accurate blood pressure measurement is critical for diagnosing and treating hypertension. Our study investigated the medical faculty students’ adherence to international blood pressure measurement recommendations. Methods: Three hundred fifteen final-year medical students from University and due to graduate in 2021 and 2022 were included in the study. These were asked 21 questions evaluating the different blood pressure measurement steps. The responses were then compared with the guideline recommendations. Results: Of the students, 55.2% were women and 65.7% were 2021 graduates. The majority (69.2%) of the students preferred aneroid devices, while 19.7% selected mercury devices for measurement, and 47.6% paid attention to calibration and validation during device selection. Most participants (92.1%) reported taking measurements sitting, with the back supported and the legs uncrossed. While 62.9% measured blood pressure from both arms at the initial visit, only 37.8% investigated all affecting factors before measurement. Seventy-four percent of the students answered the cuff deflation rate correctly. Approximately half (55.2%) recorded the measured values by rounding them up or down to the nearest even number. Although more than 50% of students answered most of the questions in line with the guidelines, only 1 student completed all the steps appropriately. Conclusion: The results of this study showed that students did not fully comply with the measurement recommendations. Considering the importance of accurate blood pressure measurement to public health, it would be beneficial to reorganize the medical education curriculum and repeat it regularly. Cite this article as: Canturk C, Turkmen E, Dilek M, Sayarlioglu H, Arik N. Clinical skills training: Do medical students have enough knowledge of accurate blood pressure measurement when they graduate? Turk J Nephrol. 2024;33(1):33-39
- 28 November 2023
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 33 (1) , 33-39
Open AccessClinical Skills Training: Do Medical Students Have Enough Knowledge of Accurate Blood Pressure Measurement When They Graduate?
Objective: Accurate blood pressure measurement is critical for diagnosing and treating hypertension. Our study investigated the medical faculty students’ adherence to international blood pressure measurement recommendations. Methods: Three hundred fifteen final-year medical students from University and due to graduate in 2021 and 2022 were included in the study. These were asked 21 questions evaluating the different blood pressure measurement steps. The responses were then compared with the guideline recommendations. Results: Of the students, 55.2% were women and 65.7% were 2021 graduates. The majority (69.2%) of the students preferred aneroid devices, while 19.7% selected mercury devices for measurement, and 47.6% paid attention to calibration and validation during device selection. Most participants (92.1%) reported taking measurements sitting, with the back supported and the legs uncrossed. While 62.9% measured blood pressure from both arms at the initial visit, only 37.8% investigated all affecting factors before measurement. Seventy-four percent of the students answered the cuff deflation rate correctly. Approximately half (55.2%) recorded the measured values by rounding them up or down to the nearest even number. Although more than 50% of students answered most of the questions in line with the guidelines, only 1 student completed all the steps appropriately. Conclusion: The results of this study showed that students did not fully comply with the measurement recommendations. Considering the importance of accurate blood pressure measurement to public health, it would be beneficial to reorganize the medical education curriculum and repeat it regularly. Cite this article as: Canturk C, Turkmen E, Dilek M, Sayarlioglu H, Arik N. Clinical skills training: Do medical students have enough knowledge of accurate blood pressure measurement when they graduate? Turk J Nephrol. 2024;33(1):33-39
- 26 September 2022
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 3 (3) , 247-253
Böbrek nakli ve hemodiyaliz hastalarında yaşam kalitesini etkileyen faktörler farklılık göstermektedir
Aim: Renal replacement therapies (RRT), including dialysis modalities and renal transplantation (RT), affect patients’ quality of life (QoL) differently. This study aimed to determine the factors affecting the QoL in hemodialysis (HD) and RT patients. Material and Method: One hundred patients in each RT and HD group were included in the study. Socio-demographic data was determined with a questionnaire. Laboratory information and other medical information of the patients were obtained from the medical records. Short Form-36 (SF-36) and Nottingham Health Profile (NHP) scales were used to assess the QoL. Results: The mean ages in HD and RT patients were 58.28±15.21 and 47.92±12.01 years. Most patients were male (53% HD, 68% RT). RT patients had a higher QoL than HD patients in all components. On the NHP scale, RT patients had higher QoL in all parts except social isolation and emotional reactions. Male gender, non-smoker status, high education level, being employed and living in the city, and some laboratory parameters (hemoglobin, ferritin, sodium, calcium, magnesium, and albumin) positively affected the QoL in the HD group; diabetes and CVD had a negative impact on the QoL. In the RT group, male gender, high education level, being employed; normal potassium, phosphorus, and parathormone levels affect QoL positively while hypertension and CVD negatively affect the QoL. Conclusion: Factors affecting QoL in patients receiving RRT are different. Efforts to correct laboratory parameters may impact the quality of life in HD patients. Returning to working life could increase the QoL in RT patients.
- 26 September 2022
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 3 (3) , 247-253
Böbrek nakli ve hemodiyaliz hastalarında yaşam kalitesini etkileyen faktörler farklılık göstermektedir
Aim: Renal replacement therapies (RRT), including dialysis modalities and renal transplantation (RT), affect patients’ quality of life (QoL) differently. This study aimed to determine the factors affecting the QoL in hemodialysis (HD) and RT patients. Material and Method: One hundred patients in each RT and HD group were included in the study. Socio-demographic data was determined with a questionnaire. Laboratory information and other medical information of the patients were obtained from the medical records. Short Form-36 (SF-36) and Nottingham Health Profile (NHP) scales were used to assess the QoL. Results: The mean ages in HD and RT patients were 58.28±15.21 and 47.92±12.01 years. Most patients were male (53% HD, 68% RT). RT patients had a higher QoL than HD patients in all components. On the NHP scale, RT patients had higher QoL in all parts except social isolation and emotional reactions. Male gender, non-smoker status, high education level, being employed and living in the city, and some laboratory parameters (hemoglobin, ferritin, sodium, calcium, magnesium, and albumin) positively affected the QoL in the HD group; diabetes and CVD had a negative impact on the QoL. In the RT group, male gender, high education level, being employed; normal potassium, phosphorus, and parathormone levels affect QoL positively while hypertension and CVD negatively affect the QoL. Conclusion: Factors affecting QoL in patients receiving RRT are different. Efforts to correct laboratory parameters may impact the quality of life in HD patients. Returning to working life could increase the QoL in RT patients.
- 20 September 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 27 (2) , 314-319
Evaluation of complications in urgent start peritoneal dialysis: Single‐center experience
Background: Patients who were urgent start peritoneal dialysis (USPD) were evaluated in terms of complications.Methods: The data from 102 patients (43 males and 59 females, mean age 58.18 ± 15.3 years) who were on peritoneal dialysis with a placed catheter between January 2014 and June 2019 in our Nephrology clinic was evaluated. The patients were divided into three groups according to the starting time of peritoneal dialysis. The development of complications between the groups (peritonitis, leakage, hernia), hemodialysis return time and overall survival times were compared.Results: There was no difference between the groups in terms of survival and complications. Diabetes, advanced age, albumin values were found to be risk factors for mortality, while no differences were found between the groups in terms of complications and mortality.Conclusion: USPD can be recommended for both because it provides a permanent dialysis option and because it leads to fewer complications than urgent start HD.
- 20 September 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 27 (2) , 314-319
Evaluation of complications in urgent start peritoneal dialysis: Single‐center experience
Background: Patients who were urgent start peritoneal dialysis (USPD) were evaluated in terms of complications.Methods: The data from 102 patients (43 males and 59 females, mean age 58.18 ± 15.3 years) who were on peritoneal dialysis with a placed catheter between January 2014 and June 2019 in our Nephrology clinic was evaluated. The patients were divided into three groups according to the starting time of peritoneal dialysis. The development of complications between the groups (peritonitis, leakage, hernia), hemodialysis return time and overall survival times were compared.Results: There was no difference between the groups in terms of survival and complications. Diabetes, advanced age, albumin values were found to be risk factors for mortality, while no differences were found between the groups in terms of complications and mortality.Conclusion: USPD can be recommended for both because it provides a permanent dialysis option and because it leads to fewer complications than urgent start HD.
- Open Access
- 31 August 2022
- Published by Ordu University in MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE
- Vol. 8 (3) , 422-431
Effects of Uric Acid on Disease Severity and Mortality in Hospitalized Covid-19 Patients
Objective: High and low uric acid (UA) levels in the general population are associated with mortality. Information on the association of UA levels with clinical outcomes in COVID-19 patients is contradictory. We investigated the relationship between UA levels and clinical endpoints in COVID-19 patients. Methods: Laboratory and clinical parameters, including UA at the admission of hospitalized COVID-19 patients, were recorded retrospectively. Binary logistic regression analysis determined risk factors for mortality and the intensive care unit (ICU) needs. Results: This study included 708 patients (57.1% men), and the median age was 63 (18-98) years. Two hundred and three (28.7%) patients needed ICU, and 107 (15.7%) died. Uric acid levels were significantly higher in the deceased (6.5 vs. 4.9; pmedian value 5.1 mg/dL) group have higher mortality rate (22.4% vs. 9.5%; p<0.001). In multivariate analyses, a high UA level was a risk factor for mortality [OR 1.93 (1.08 – 3.44); p=0.026]. In addition, age [OR 1.03 (1.01 – 1.05); p=0.004], albumin [OR 0.30 (0.17 - 0.52); P<0.001], neutrophil-to-lymphocyte ratio [OR 1.04 (1.01 – 1.06); p=0.003] and procalcitonin [OR 1.06 (1.0 – 1.11); p=0.048] was associated with mortality. A high UA level was not a risk factor for ICU need (p=0.780). Conclusion: High serum UA level affects mortality in COVID-19 patients. Risk assessment for the prognosis of patients can be made according to the UA levels at admission.
- 31 August 2022
- Published by Ordu University in MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE
- Vol. 8 (3) , 422-431
Open AccessEffects of Uric Acid on Disease Severity and Mortality in Hospitalized Covid-19 Patients
Objective: High and low uric acid (UA) levels in the general population are associated with mortality. Information on the association of UA levels with clinical outcomes in COVID-19 patients is contradictory. We investigated the relationship between UA levels and clinical endpoints in COVID-19 patients. Methods: Laboratory and clinical parameters, including UA at the admission of hospitalized COVID-19 patients, were recorded retrospectively. Binary logistic regression analysis determined risk factors for mortality and the intensive care unit (ICU) needs. Results: This study included 708 patients (57.1% men), and the median age was 63 (18-98) years. Two hundred and three (28.7%) patients needed ICU, and 107 (15.7%) died. Uric acid levels were significantly higher in the deceased (6.5 vs. 4.9; pmedian value 5.1 mg/dL) group have higher mortality rate (22.4% vs. 9.5%; p<0.001). In multivariate analyses, a high UA level was a risk factor for mortality [OR 1.93 (1.08 – 3.44); p=0.026]. In addition, age [OR 1.03 (1.01 – 1.05); p=0.004], albumin [OR 0.30 (0.17 - 0.52); P<0.001], neutrophil-to-lymphocyte ratio [OR 1.04 (1.01 – 1.06); p=0.003] and procalcitonin [OR 1.06 (1.0 – 1.11); p=0.048] was associated with mortality. A high UA level was not a risk factor for ICU need (p=0.780). Conclusion: High serum UA level affects mortality in COVID-19 patients. Risk assessment for the prognosis of patients can be made according to the UA levels at admission.